Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Heptanoic Acids/*pharmacology"'
1
Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia
Autor: Marios A. Cariolou, George Miltiadous, Manolis Ganotakis, Eleni Bairaktari, Stavroulla Xenophontos, Moses Elisaf
Publikováno v: Pharmacogenetics and Genomics. 15:219-225
Familial hypercholesterolaemia (FH) is the most common inherited metabolic disease characterized by elevated serum levels of low-density lipoprotein cholesterol (LDL-C) and ischaemic heart disease early in life. Early diagnosis and treatment are esse
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa3c9fcaf08dba524e97aea8d54cf6f4
https://doi.org/10.1097/01213011-200504000-00005
Zobrazit plný text záznamu
3
Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study
Autor: Elisaf, Alexandros D. Tselepis, Theodosios D Filippatos, C. S. Derdemezis, Dimitri P. Mikhailidis
Introduction: Ezetimibe inhibits intestinal absorption of cholesterol and lowers circulating low-density lipoprotein cholesterol levels. Visfatin is a novel adipokine, which may be implicated in the atherosclerotic process. Objective: The aim of this
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb3e36b8dad4cbc43275210cb74812cf
http://olympias.lib.uoi.gr/jspui/handle/123456789/10564
Zobrazit plný text záznamu
4
Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia
Autor: Daskalopoulou, S. S., Tzovaras, V., Mikhailidis, D. P., Elisaf, M. S.
Beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease serum uric acid (SUA) levels, such as losartan, fenofibrate and some non-steroidal anti-inflammatory drugs (NSAIDs). Some of these drugs increase renal ur
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10561::8c637af2fbeb290878e0f9ba8acd936b
http://olympias.lib.uoi.gr/jspui/handle/123456789/22149
Zobrazit plný text záznamu
8
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia
Autor: John C. Papakostas, Moses Elisaf, Haralampos J. Milionis, Konstantine Seferiadis, Anna I. Kakafika, George Chasiotis
Hyperhomocysteinemia is regarded as an independent risk factor for cardiovascular disease. Lipid-lowering agents, such as fibrates, can modify homocysteine levels. However, less is known about the effect of statin therapy on homocysteine. The authors
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb90bac512a973a58bcca9d659208e5c
http://olympias.lib.uoi.gr/jspui/handle/123456789/22936
Zobrazit plný text záznamu
9
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB
Autor: Tsimihodimos, V., Karabina, S. A., Tambaki, A. P., Bairaktari, E., Goudevenos, J. A., Chapman, M. J., Elisaf, M. S., Tselepis, A. D.
Human plasma platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A(2) that is primarily associated with low density lipoprotein (LDL). PAF-AH activity has also been found in high density lipoprotein (HDL), although it has recently
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::05243efa385e4e361b818f3bbc7943a1
http://olympias.lib.uoi.gr/jspui/handle/123456789/9943
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje